This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Calcitonin - RCP evidence grades in osteoporosis

Authoring team

Spine: A Non-vertebral: B Hip: B

In a five year blind, randomised placebo controlled trial of 1,255 postmenopausal women with established osteoporosis, patients received either placebo or increasing doses of intranasal calcitonin upto 400 IU daily. All patients received vitamin D + calcium. Bone mineral density at the spine increased from 0.7 to 1.6% inthe treatment groups. No differences were observed at the hip. There was a decrease in the risk of new or worsening spinal deformity inthe 200 IU daily category.

A systematic review of calcitonin on fracture rates revealed significant decreases in vertebral and non-vetebral fractures but these benefits seem lower than those observed in trials with bisphosphonates.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.